← FDA DRUG APPROVALS

FDA ANDA · ANDA204570

TESTOSTERONE

Sponsor: ACTAVIS LABS UT INC

APPLICATION
ANDA204570
TYPE
ANDA
ORIGINAL APPROVAL
2019-04-10
LATEST ACTION
2019-11-01
ROUTE
TRANSDERMAL
DOSAGE FORM
GEL, METERED, GEL
MARKETING STATUS
Prescription

Products

TESTOSTERONEPrescription
TESTOSTERONE 1.62% (20.25MG/1.25GM ACTUATION) · GEL, METERED · TRANSDERMAL
TESTOSTERONEPrescription
TESTOSTERONE 1.62% (20.25MG/1.25GM PACKET) · GEL · TRANSDERMAL
TESTOSTERONEPrescription
TESTOSTERONE 1.62% (40.5MG/2.5GM PACKET) · GEL · TRANSDERMAL

Approval history

2019-11-01Labeling · Supplement 2 · standardAP
2019-05-16Labeling · Supplement 1 · standardAP
2019-04-10UNKNOWN · OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →